Sponsor	Institut National de la Santé et de la Recherche Médicale (Inserm)
Title	Non interventional study of the management of patients with Idiopathic Pulmonary Fibrosis (IPF) in clinical (real world) practice: a specific research project from the RaDiCo-PID (Rare Disease Cohort – Pneumopathies Interstitielles Diffuses) cohort. Caractéristiques des patients atteint de FIP et évaluation de la mortalité et de la morbidité chez les patients traités par Ofev® (nintedanib). Characteristics of patients diagnosed with IPF and assessment of the mortality and morbidity among patients treated with Ofev® (nintedanib).
Country	France
Private partner	Boehringer Ingelheim
Research Question and Objectives	In the context of the clinical assessment of Ofev® by HAS, Transparency Commission requested "real-world practice data on the characteristics of treated patients, and the impact of this drug in terms of morbidity and mortality, to be provided". In line with HAS' requests and the design of the study, the objectives of this post-registration investigation are: ✓ Primary objective: To describe the characteristics of patients diagnosed with IPF in France ✓ Secondary objective: To assess the morbidity and mortality in patients treated with nintedanib in real-world practice in France.
Population	IPF diagnosis less than 3 years included in RaDiCo-PID between July 2017 and July 2019.
Regulatory	Cohort RaDiCo-PID protocol, sponsored by Inserm, receiving a favorable opinion of Inserm Ethics Committee on 16 October 2015 and of CCTIRS on 23 March 2016. CNIL approved Cohort RaDiCo-PID protocol on 3 November 2016.